Page last updated: 2024-10-31

methylphenidate and Genetic Predisposition

methylphenidate has been researched along with Genetic Predisposition in 19 studies

Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.
methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.
methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.

Research Excerpts

ExcerptRelevanceReference
"Narcolepsy is an emblematic, unique disease within sleep disorders that is characterised by excessive daytime sleepiness, cataplexy and other abnormal manifestations of REM sleep."2.48[Diagnostic and therapeutic update in narcolepsy]. ( Santamaria-Cano, J, 2012)
"Although dyslexia is widely diagnosed and affects a very important portion of the childhood population, a conceptual definition of the condition is still lacking."1.35[Dyslexia: a disease, a disorder or something else?]. ( Artigas-Pallarés, J, 2009)

Research

Studies (19)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's8 (42.11)29.6817
2010's11 (57.89)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Akay, AP1
Kaya, GÇ1
Kose, S1
Yazıcıoğlu, ÇE1
Erkuran, HÖ1
Güney, SA1
Oğuz, K1
Keskin, D1
Baykara, B1
Emiroğlu, Nİ1
Eren, MŞ1
Kızıldağ, S1
Ertay, T1
Özsoylu, D1
Miral, S1
Durak, H1
Gönül, AS1
Rohde, LA1
Tarver, J1
Daley, D1
Sayal, K1
Eyre, HA1
Eskin, A1
Nelson, SF1
St Cyr, NM1
Siddarth, P1
Baune, BT1
Lavretsky, H1
Sengupta, S1
Grizenko, N2
Schmitz, N1
Schwartz, G1
Bellingham, J1
Polotskaia, A1
Stepanian, MT1
Goto, Y1
Grace, AA1
Joober, R2
Yan, TC1
McQuillin, A1
Thapar, A1
Asherson, P1
Hunt, SP1
Stanford, SC1
Gurling, H1
Artigas-Pallarés, J1
Banaschewski, T1
Konrad, K1
Rothenberger, A1
Hebebrand, J1
Won, H1
Mah, W1
Kim, E2
Kim, JW3
Hahm, EK1
Kim, MH1
Cho, S1
Kim, J1
Jang, H1
Cho, SC3
Kim, BN3
Shin, MS3
Seo, J1
Jeong, J1
Choi, SY1
Kim, D1
Kang, C1
Jain, M1
Vélez, JI1
Acosta, MT1
Palacio, LG1
Balog, J1
Roessler, E1
Pineda, D1
Londoño, AC1
Palacio, JD1
Arbelaez, A1
Lopera, F1
Elia, J1
Hakonarson, H1
Seitz, C1
Freitag, CM1
Palmason, H1
Meyer, J1
Romanos, M1
Walitza, S1
Hemminger, U1
Warnke, A1
Romanos, J1
Renner, T1
Jacob, C1
Lesch, KP1
Swanson, J1
Castellanos, FX1
Bailey-Wilson, JE1
Arcos-Burgos, M1
Muenke, M1
Cummins, TD1
Bellgrove, MA1
Hong, SB2
Song, SH1
Kim, JH1
Son, JW1
Shin, YM1
Chung, US1
Han, DH1
Trujillo-Orrego, N1
Ibáñez, A1
Pineda, DA1
Park, S1
Yang, YH1
Park, MH1
Yoo, HJ1
Santamaria-Cano, J1
Fortier, MÈ1
Sengupta, SM1
Choudhry, Z1
Thakur, G1
Abramowicz, MJ1
Van Haecke, P1
Demedts, M1
Delcroix, M1
Siesser, WB1
Zhao, J1
Miller, LR1
Cheng, SY1
McDonald, MP1
Faraone, SV1
Biederman, J1
Spencer, T1
Wilens, T1
Seidman, LJ1
Mick, E1
Doyle, AE1
Ripley, A1
Denney, CB1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Use of Methylphenidate to Improve Clinical Outcomes in Geriatric Depression: A Double-blind Placebo-Controlled Trial of Methylphenidate (Ritalin) Augmentation of Citalopram (Celexa) in Depressed Elderly Patients[NCT00602290]Phase 4181 participants (Actual)Interventional2008-02-29Completed
Candidate Gene Screening for 6-14 Year Old Patients With ADHD (Attention Deficit/ Hyperactivity Disorder)[NCT03018574]100 participants (Actual)Observational2016-05-31Completed
An Open-label Prospective Trial to Evaluate Functional Outcomes of OROS Methylphenidate in Children With ADHD (FOSCO)[NCT01012622]Phase 4142 participants (Actual)Interventional2008-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Hamilton Depression Rating Scale (HDRS) Maintained Scores at Week 16

The Hamilton Depression Rating Scale (HDRS) is a 24-item depression scale and the total score is summed with a minimum score=0 and maximum score=76. There are no subscales and the higher values represent a worse outcome. Outcomes are measured and defined as follows: 1) Response will be defined as HDRS scores of 10 or less; 2) Sustained response will be defined as maintained response at week 16; 4) Remission will be defined as HDRS scores of 6 or less. (NCT00602290)
Timeframe: Maintained response measured at Week 16

Interventionunits on a scale (Mean)
1 - Citalopram + Placebo18.3
2 - Methylphenidate + Placebo18.7
3 - Methylphenidate + Citalopram19.8

Quality of Life Assessment

The Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) is a 16 item self-administered questionnaire that captures life satisfaction over the past week. Each question is rated on a 5 point scale from 1 (Very Poor) to 5 (Very Good). The total score is reported for items 1-14. The minimum raw score on the Q-LES-Q-SF is 14, and the maximum score is 70 with higher values representing a better outcome. (NCT00602290)
Timeframe: Measured at Baseline and Week 16

,,
Interventionunits on a scale (Mean)
BaselineWeek 16
1 - Citalopram + Placebo45.5054.45
2 - Methylphenidate + Placebo47.0653.54
3 - Methylphenidate + Citalopram47.5257.79

Number of Participants With Remission Based on K-ARS Total Score and Clinical Global Impression - Improvement (CGI-I) Scale Score at Week 12

"Remission is defined by all of the following criteria; 1) K-ARS Total score of 18 or less. 2) Very much improved or Much improved in CGI-I. K-ARS total score ranges from 0 (no symptoms) to 54 (highly symptomatic), higher score indicates worsening of condition. CGI-I is a 7-point scale ranging from 1 to 7, where 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse, higher score indicates worsening of condition." (NCT01012622)
Timeframe: Week 12

Interventionparticipants (Number)
Osmotic Release Oral System (OROS) Methylphenidate HCL99

Number of Participants With Response Based on K-ARS Total Score at Week 12

Response is defined as at least 25 percent (%) decrease in total score of K-ARS compared to baseline. K-ARS measures the 18 symptoms based on DSM-IV (1994). Individual item scores range from 0 (none/never or rarely) to 3 (severe/very often), whereas the rating of 2 points or more was regarded as abnormal. Total scores range from 0 (no symptoms) to 54 (highly symptomatic), higher score indicates worsening of condition. (NCT01012622)
Timeframe: Week 12

Interventionparticipants (Number)
Osmotic Release Oral System (OROS) Methylphenidate HCL118

Change From Baseline in Academic Performance Rating Scale (APRS) Score at Week 12

APRS scale measures four factors in elementary school children such as learning ability, academic performance, impulse control, and social withdrawal. In particular, it is excellent in assessing drug effect on the academic performance not measured by other scales. Score ranges from 19 to 95, higher score means better academic performance. (NCT01012622)
Timeframe: Baseline and Week 12

Interventionunits on a scale (Mean)
BaselineChange at Week 12
Osmotic Release Oral System (OROS) Methylphenidate HCL55.467.40

Change From Baseline in Auditory Selective Attention Subtest of Comprehensive Attention Test (CAT) Total Score at Week 12

CAT was developed to properly reflect brain function in childhood. It provided measurement of simple auditory selective attention in terms of omission (number of missing response to target stimulus [0-150], higher score indicate greater omission), false alarm (number of response to non-target stimulus [0-150], higher score indicate greater false alarm), response mean (average time spent to response to target stimulus [200-1100, low score means faster response to target stimulus]), Response (consistency of response time to target stimulus [30-650, Low score means good consistency of response]). (NCT01012622)
Timeframe: Baseline and Week 12

Interventionunits on a scale (Mean)
Omission:BaselineOmission:Change at Week 12False alarm:BaselineFalse alarm:Change at Week 12Response mean:BaselineResponse mean:Change at Week 12Response:BaselineResponse:Change at Week 12
Osmotic Release Oral System (OROS) Methylphenidate HCL10.31-6.2712.07-3.61623.95-55.34265.69-63.76

Change From Baseline in Beck Depression Inventory (BDI) Score at Week 12

Beck Depression Inventory (BDI) consisted of 21 items for measuring the subjective severity of depression and emotional, cognitive, motivational, physiological symptoms of depression. Each question has a set of 4 possible answer choices, ranging in intensity, each answer being scored on a scale value of 0 (no symptom) to 3 (the most severe symptom). Accordingly, the total score ranges from 0 (no symptom) to 63 (the most severe symptom) for 21 questions. (NCT01012622)
Timeframe: Baseline and Week 12

Interventionunits on a scale (Mean)
BaselineChange at Week 12
Osmotic Release Oral System (OROS) Methylphenidate HCL11.69-1.89

Change From Baseline in Child Health and Illness Profile-Child Edition (CHIP) Total Score and 5 Sub-domains Score at Week 12

CHIP was designed to assess the physical, psychological health conditions and functional well-being of children. The instrument has sub-domains such satisfaction (11 items) ranges from 0 to 44, stability (22 items) ranges from 0 to 88, elasticity (19 items) ranges from 0 to 76, risk aversion (14 items) ranges from 0 to 56, achievement (10 items) ranges from 0 to 40. Good health is in the range from 44 to 56 points for all sub-domains. A score of 43 or below indicates poor health in that domain. A score of 57 or higher indicates excellent health. The total score is an average of the scores for the 5 domains and ranges from 0 to 304. Higher total score indicates better health. (NCT01012622)
Timeframe: Baseline and Week 12

Interventionunits on a scale (Mean)
Total Score:Baseline (n=126)Total Score:Change at Week 12 (n=126)Satisfaction:Baseline (n=132)Satisfaction:Change at Week 12 (n=132)Stability:Baseline (n=129)Stability:Change at Week 12 (n=129)Elasticity:Baseline (n=132)Elasticity:Change at Week 12 (n=132)Risk aversion:Baseline (n=132)Risk aversion:Change at Week 12 (n=132)Achievement:Baseline (n=133)Achievement:Change at Week 12 (n=133)
Osmotic Release Oral System (OROS) Methylphenidate HCL207.8518.0826.172.2782.134.4738.302.5340.675.7321.002.45

Change From Baseline in Clinical Global Impression-severity (CGI-S) Score at Week 12

"The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to Normal, not at all ill and a rating of 7 is equivalent to Among the most extremely ill participants. Higher change scores indicate worsening." (NCT01012622)
Timeframe: Baseline and Week 12

Interventionunits on a scale (Mean)
BaselineChange at Week 12
Osmotic Release Oral System (OROS) Methylphenidate HCL5.14-2.51

Change From Baseline in Divided Attention Subtest of Comprehensive Attention Test (CAT) at Week 12

CAT was developed to properly reflect brain function in childhood. It provided measurement of simple divided attention in terms of omission(number of missing response to target stimulus[0-150], higher score indicate greater omission), false alarm(number of response to non-target stimulus[0-150], higher score indicate greater false alarm), response mean (average time spent to response to target stimulus [200-1100, low score means faster response to target stimulus]), Response (consistency of response time to target stimulus [30-650, Low score means good consistency of response]). (NCT01012622)
Timeframe: Baseline and Week 12

Interventionunits on a scale (Mean)
Omission:BaselineOmission:Change at Week 12False alarm:BaselineFalse alarm:Change at Week 12Response mean:BaselineResponse mean:Change at Week 12Response:BaselineResponse:Change at Week 12
Osmotic Release Oral System (OROS) Methylphenidate HCL16.05-4.0716.03-4.73749.01-27.14349.60-43.90

Change From Baseline in Inhibition-Sustained Attention Subtest of Comprehensive Attention Test (CAT) Total Score at Week 12

CAT was developed to properly reflect brain function in childhood. It provided measurement of simple inhibition-sustained attention in terms of omission(number of missing response to target stimulus [0-150], higher score indicate greater omission), false alarm(number of response to non-target stimulus [0-150], higher score indicate greater false alarm), response mean (average time spent to response to target stimulus [200-1100, low score means faster response to target stimulus]), Response (consistency of response time to target stimulus [30-650, Low score means good consistency of response]). (NCT01012622)
Timeframe: Baseline and Week 12

Interventionunits on a scale (Mean)
Omission:BaselineOmission:Change at Week 12False alarm:BaselineFalse alarm:Change at Week 12Response mean:BaselineResponse mean:Change at Week 12Response:BaselineResponse:Change at Week 12
Osmotic Release Oral System (OROS) Methylphenidate HCL35.78-20.3927.73-7.54576.55-34.44273.78-66.85

Change From Baseline in Interference-Selective Attention Subtest of Comprehensive Attention Test (CAT) Total Score at Week 12

CAT was developed to properly reflect brain function in childhood. It provided measurement of simple interference-selective attention in terms of omission(number of missing response to target stimulus[0-150], higher score indicate greater omission), false alarm(number of response to non-target stimulus[0-150], higher score indicate greater false alarm), response mean (average time spent to response to target stimulus [200-1100, low score means faster response to target stimulus]), Response (consistency of response time to target stimulus [30-650, Low score means good consistency of response]). (NCT01012622)
Timeframe: Baseline and Week 12

Interventionunits on a scale (Mean)
Omission:BaselineOmission:Change at Week 12False alarm:BaselineFalse alarm:Change at Week 12Response mean:BaselineResponse mean:Change at Week 12Response:BaselineResponse:Change at Week 12
Osmotic Release Oral System (OROS) Methylphenidate HCL20.39-10.8326.03-6.14648.48-54.35276.74-72.18

Change From Baseline in Korean Version of the Attention-Deficit Hyperactivity Disorder (K-ADHD) Rating Scale (K-ARS) Total Score at Week 12

K-ARS measures the 18 symptoms based on Diagnostic and Statistical Manual of Mental Disorders-forth edition (DSM-IV 1994). Individual item scores range from 0 (none/never or rarely) to 3 (severe/very often), whereas the rating of 2 points or more was regarded as abnormal. Total scores range from 0 (no symptoms) to 54 (highly symptomatic), higher score indicates worsening of condition. (NCT01012622)
Timeframe: Baseline and Week 12

Interventionunits on a scale (Mean)
BaselineChange at Week 12
Osmotic Release Oral System (OROS) Methylphenidate HCL33.37-20.43

Change From Baseline in Parenting Stress Index (PSI) Total Score at Week 12

"Parenting Stress Index (PSI) was designed to assess parent or guardian child-rearing stress index on a 5-rating scale from never to very truly. Out of 30 items, 20 items are scored, being consisted of 8 child characteristics-related stress items; 9 parent-child interaction-related stress items; and 3 achievement expectation-related stress items. A possible total score ranges from 20 to 100; Increase in score indicates higher stress perceived by the parent." (NCT01012622)
Timeframe: Baseline and Week 12

Interventionunits on a scale (Mean)
BaselineChange at Week 12
Osmotic Release Oral System (OROS) Methylphenidate HCL58.20-5.25

Change From Baseline in Visual Selective Attention Subtest of Comprehensive Attention Test (CAT) Total Score at Week 12

CAT was developed to properly reflect brain function in childhood. It provided measurement of simple visual selective attention in terms of omission (number of missing response to target stimulus [0-150], higher score indicate greater omission), false alarm (number of response to non-target stimulus [0-150], higher score indicate greater false alarm), response mean (average time spent to response to target stimulus [200-1100, low score means faster response to target stimulus]), Response (consistency of response time to target stimulus [30-650, Low score means good consistency of response]). (NCT01012622)
Timeframe: Baseline and Week 12

Interventionunits on a scale (Mean)
Omission:BaselineOmission:Change at Week 12False alarm:BaselineFalse alarm:Change at Week 12Response mean:BaselineResponse mean:Change at Week 12Response:BaselineResponse:Change at Week 12
Osmotic Release Oral System (OROS) Methylphenidate HCL8.79-4.5317.42-5.03501.32-37.41201.05-48.36

Change From Baseline in Working Memory Backward Subtest of Comprehensive Attention Test (CAT) at Week 12

CAT was developed to properly reflect brain function in childhood. The test battery provided a comprehensive measurement of simple visual auditory attention, interventional visual-auditory selective attention, divided attention, continuous attention, and operational memory. Working memory forward was measured in terms of width of space and number of correct responses ranging from 0 to 10. For width of space boxes were presented on the screen and participants remembered the order of presented box. Participants pressed the box using mouse in the backward order. Maximum number that participants correctly memorized box in the screen in the respective order was reported and overall number of times a participant responded correctly was also reported. (NCT01012622)
Timeframe: Baseline and Week 12

Interventioncorrect responses (Mean)
Baseline:Number of correct responsesChange at Week 12:Number of correct responsesBaseline:Spatial spanChange at Week 12:Spatial span
Osmotic Release Oral System (OROS) Methylphenidate HCL4.221.863.631.24

Change From Baseline in Working Memory Forward Subtest of Comprehensive Attention Test (CAT) at Week 12

CAT was developed to properly reflect brain function in childhood. The test battery provided a comprehensive measurement of simple visual auditory attention, interventional visual-auditory selective attention, divided attention, continuous attention, and operational memory. Working memory forward was measured in terms of width of space and number of correct responses ranging from 0 to 10. For width of space boxes were presented on the screen and participants remembered the order of presented box. Participants pressed the box using mouse in the forward order. Maximum number that participants correctly memorized box in the screen in the respective order was reported and overall number of times a participant responded correctly was also reported. (NCT01012622)
Timeframe: Baseline and Week 12

Interventioncorrect responses (Mean)
Baseline:Number of correct responsesChange at Week 12:Number of correct responsesBaseline:Width of spaceChange at Week 12:Width of space
Osmotic Release Oral System (OROS) Methylphenidate HCL5.760.634.460.25

Clinical Global Impression - Improvement (CGI-I) Scale Score at Week 12

The CGI-I is a 7-point scale that requires the clinician to assess how much the participant's illness has improved or worsened relative to a baseline state at the beginning of the intervention and rated as: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse. Improved very much, Improved much and Improved a little are defined as improvement and No change, Aggravated a little, Aggravated much and Aggravated very much were defined as aggravation. (NCT01012622)
Timeframe: Week 12

Interventionparticipants (Number)
ImprovementAggravation
Osmotic Release Oral System (OROS) Methylphenidate HCL1227

Reviews

7 reviews available for methylphenidate and Genetic Predisposition

ArticleYear
Attention-deficit hyperactivity disorder (ADHD): an updated review of the essential facts.
    Child: care, health and development, 2014, Volume: 40, Issue:6

    Topics: Attention Deficit Disorder with Hyperactivity; Brain; Child; Child Behavior Disorders; Child Develop

2014
[Attention deficit hyperactivity disorder].
    Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie, 2009, Volume: 37, Issue:4

    Topics: Adolescent; Animals; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System St

2009
[Diagnostic validity of attention deficit/hyperactivity disorder: from phenomenology to neurobiology (II)].
    Revista de neurologia, 2012, Mar-16, Volume: 54, Issue:6

    Topics: Attention; Attention Deficit Disorder with Hyperactivity; Brain; Brain Mapping; Cognition; Diagnosti

2012
[Diagnostic and therapeutic update in narcolepsy].
    Revista de neurologia, 2012, May-21, Volume: 54 Suppl 3

    Topics: Adolescent; Adult; Age of Onset; Animals; Autoimmune Diseases; Benzhydryl Compounds; Cataplexy; Chil

2012
Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation.
    The European respiratory journal, 2003, Volume: 22, Issue:3

    Topics: Adult; Appetite Depressants; Attention Deficit Disorder with Hyperactivity; Bone Morphogenetic Prote

2003
Attention-deficit/hyperactivity disorder in adults: an overview.
    Biological psychiatry, 2000, Jul-01, Volume: 48, Issue:1

    Topics: Adult; Age Factors; Antidepressive Agents, Tricyclic; Attention Deficit Disorder with Hyperactivity;

2000
Stimulant effects in attention deficit hyperactivity disorder: theoretical and empirical issues.
    Journal of clinical child psychology, 2001, Volume: 30, Issue:1

    Topics: Adolescent; Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulant

2001

Trials

4 trials available for methylphenidate and Genetic Predisposition

ArticleYear
Genomic predictors of remission to antidepressant treatment in geriatric depression using genome-wide expression analyses: a pilot study.
    International journal of geriatric psychiatry, 2016, Volume: 31, Issue:5

    Topics: Aged; Aged, 80 and over; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Dopamine Upt

2016
COMT Val108/158Met polymorphism and the modulation of task-oriented behavior in children with ADHD.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2008, Volume: 33, Issue:13

    Topics: Amino Acid Substitution; Attention Deficit Disorder with Hyperactivity; Catechol O-Methyltransferase

2008
Val/Val genotype of brain-derived neurotrophic factor (BDNF) Val⁶⁶Met polymorphism is associated with a better response to OROS-MPH in Korean ADHD children.
    The international journal of neuropsychopharmacology, 2011, Volume: 14, Issue:10

    Topics: Administration, Oral; Age Factors; Analysis of Variance; Attention Deficit Disorder with Hyperactivi

2011
Genetic evidence for the association of the hypothalamic-pituitary-adrenal (HPA) axis with ADHD and methylphenidate treatment response.
    Neuromolecular medicine, 2013, Volume: 15, Issue:1

    Topics: Attention Deficit Disorder with Hyperactivity; Child; Child Behavior Disorders; Dexamethasone; Doubl

2013

Other Studies

8 other studies available for methylphenidate and Genetic Predisposition

ArticleYear
Genetic imaging study with [Tc-
    Progress in neuro-psychopharmacology & biological psychiatry, 2018, 08-30, Volume: 86

    Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Brain; Brain Mapping; Central Nervous Sys

2018
NK1 (TACR1) receptor gene 'knockout' mouse phenotype predicts genetic association with ADHD.
    Journal of psychopharmacology (Oxford, England), 2010, Volume: 24, Issue:1

    Topics: Animals; Attention Deficit Disorder with Hyperactivity; Base Sequence; Case-Control Studies; Corpus

2010
[Dyslexia: a disease, a disorder or something else?].
    Revista de neurologia, 2009, Feb-27, Volume: 48 Suppl 2

    Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Dyslexia; G

2009
GIT1 is associated with ADHD in humans and ADHD-like behaviors in mice.
    Nature medicine, 2011, Volume: 17, Issue:5

    Topics: Adaptor Proteins, Signal Transducing; Amphetamine; Animals; Attention Deficit Disorder with Hyperact

2011
A cooperative interaction between LPHN3 and 11q doubles the risk for ADHD.
    Molecular psychiatry, 2012, Volume: 17, Issue:7

    Topics: Aspartic Acid; Attention Deficit Disorder with Hyperactivity; Brain; Case-Control Studies; Choline;

2012
Possible effect of norepinephrine transporter polymorphisms on methylphenidate-induced changes in neuropsychological function in attention-deficit hyperactivity disorder.
    Behavioral and brain functions : BBF, 2012, May-16, Volume: 8

    Topics: Adolescent; Alleles; Attention; Attention Deficit Disorder with Hyperactivity; Child; Female; Gene F

2012
Transgenic mice expressing a human mutant beta1 thyroid receptor are hyperactive, impulsive, and inattentive.
    Genes, brain, and behavior, 2006, Volume: 5, Issue:3

    Topics: Age Factors; Analysis of Variance; Animals; Attention; Attention Deficit Disorder with Hyperactivity

2006
Ritalin: mom's little helper. A disorder long linked to sons migrates up the family tree.
    Time, 2001, Feb-12, Volume: 157, Issue:6

    Topics: Adult; Attention Deficit Disorder with Hyperactivity; Child; Female; Genetic Predisposition to Disea

2001